Tenon Medical Inc

Tenon Medical Inc(TNON)の株式分析

$5.000

-0.020 (-0.40%)終値時点

Loading chart…
High
5.620
Open
5.460
VWAP
5.12
Vol
7.76M
Mkt Cap
2.31M
Low
4.750
Amount
39.73M
EV/EBITDA, TTM
-0.30

Tenon Medical, Inc. is a medical device company. The Company has developed the Catamaran SI Joint Fusion System that offers a novel, less invasive approach to the SI joint using a single, robust titanium implant. The system features the Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, stabilizing and transfixing the SI Joint along its longitudinal axis. The angle and trajectory of the Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular structures and into the strongest cortical bone. Its trademarks include Catamaran, PiSIF, CAT PiSIF, ETAD, CAT SIJ Fusion System, SImmetry, MAINSAIL, SImmetry+, Catamaran Transfixation Fusion Device, Catamaran Transfixation Fusion System, and others. The Catamaran SI Joint Fusion System offers a novel, less invasive Inferior-Posterior approach to the SI joint using a single, robust titanium implant.

AI analysis of Tenon Medical Inc (TNON)

sell

Tenon Medical Inc is not a good buy right now due to significant financial losses and declining stock performance. The current price is $5.00, which is down 85.33% year-to-date, indicating severe underperformance. Furthermore, the RSI is at 39.208, suggesting that the stock is in a bearish trend. The company reported a net loss of $4.05 million in Q2, despite a revenue increase of 128% year-over-year, highlighting ongoing financial challenges. The main risk is the widening net loss, which has increased from $2.77 million a year earlier to $4.05 million this quarter.

バリュエーション指標

The current forward P/E ratio for Tenon Medical Inc (TNON) is 0.00, compared to its 5-year average forward P/E of -3.02.

Forward P/E

Fair
5Y Average P/E
-3.02
Current P/E
0.00
割高
12.73
割安
-18.77

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
-0.04
Current EV/EBITDA
-0.30
割高
0.06
割安
-0.14

Forward P/S

Fair
5Y Average P/S
5.86
Current P/S
0.35
割高
37.01
割安
-25.28

Alphio AI Price Scenarios for TNON

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%TNON

$1.25

シナリオ価格

B

Base

Base · 50%TNON

$1.02

シナリオ価格

B

Bear

Bear · 25%TNON

$0.83

シナリオ価格

イベントタイムライン

2026-08-28 (ET)

09:30:00

Tenon Medical Enters Agreement to Sell 597,610 Shares to Institutional Investor

2026-08-19 (ET)

10:00:00

Tenon Medical Inc Trading Halted

2026-08-11 (ET)

18:00:00

Tenon Medical Files $100M Mixed Securities Shelf

2026-08-07 (ET)

20:00:00

Tenon Medical Inc Trading Halted, News Pending

2026-07-02 (ET)

08:30:00

Tenon Medical Receives FDA Clearance for Catamaran SI Joint Fusion System

ニュース

TNON FAQ — answered by Alphio AI

Tenon Medical, Inc. is a medical device company. The Company has developed the Catamaran SI Joint Fusion System that offers a novel, less invasive approach to the SI joint using a single, robust titanium implant. The system features the Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, stabilizing and transfixing the SI Joint along its longitudinal axis. The angle and trajectory of the Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular structures and into the strongest cortical bone. Its trademarks include Catamaran, PiSIF, CAT PiSIF, ETAD, CAT SIJ Fusion System, SImmetry, MAINSAIL, SImmetry+, Catamaran Transfixation Fusion Device, Catamaran Transfixation Fusion System, and others. The Catamaran SI Joint Fusion System offers a novel, less invasive Inferior-Posterior approach to the SI joint using a single, robust titanium implant. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Tenon Medical Inc is not a good buy right now due to significant financial losses and declining stock performance. The current price is $5.00, which is down 85.33% year-to-date, indicating severe underperformance. Furthermore, the RSI is at 39.208, suggesting that the stock is in a bearish trend. The company reported a net loss of $4.05 million in Q2, despite a revenue increase of 128% year-over-year, highlighting ongoing financial challenges. The main risk is the widening net loss, which has increased from $2.77 million a year earlier to $4.05 million this quarter.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める